SMS Pharmaceuticals reported a consolidated net profit attributable to shareholders of ₹20.91 crore for the quarter ended June 30, 2026, marking a 2.0% increase from ₹20.49 crore in the corresponding period of FY26. Revenue from operations grew by 5.6% year-on-year to ₹206.96 crore, driven by stable demand in its Active Pharmaceutical Ingredients (API) segment. The modest profit growth despite higher sales indicates margin pressures or increased operational costs. In corporate developments, the Board approved the re-appointment of Ramesh Babu Potluri as Chairman and Managing Director for five years and authorized an unsecured loan of up to ₹50 crore to its subsidiary, SMS Peptides Private Limited.

The standalone net profit rose 16.0% to ₹21.13 crore from ₹18.21 crore in Q1FY26, outpacing the consolidated growth due to lower associate contributions in the group figures. Earnings per share (basic and diluted) on a consolidated basis stood at ₹2.23, down from ₹2.31 in Q1FY26 but higher than the ₹2.26 reported in the preceding quarter. Statutory auditors Suryanarayana & Suresh issued an unmodified limited review report on the unaudited financial results. The Board also approved the Notice for the 38th Annual General Meeting (AGM) scheduled for September 23, 2026.

Financial Performance Overview

The company’s total income reached ₹208.71 crore in Q1FY27, compared to ₹196.64 crore in Q1FY26. While revenue from operations increased to ₹206.96 crore from ₹196.05 crore, other income declined slightly to ₹174.44 lakh from ₹59.31 lakh in the prior year quarter. Total expenses rose to ₹18,150.43 lakh from ₹17,227.12 lakh, reflecting higher cost of materials consumed at ₹13,664.68 lakh versus ₹14,528.60 lakh in Q1FY26. The share of profit from associate VKT Pharma Private Limited dropped significantly to ₹70.80 lakh from ₹177.58 lakh in Q1FY26, impacting consolidated bottom-line growth.

Note: Net Profit figures are attributed to shareholders. Consolidated net profit before share of associates was ₹20.20 crore.

Key Corporate Actions

The Board approved the re-appointment of Ramesh Babu Potluri as Chairman and Managing Director for a term of five years, effective from October 1, 2026, to September 30, 2031, subject to shareholder approval. This follows the recommendation of the Nomination and Remuneration Committee. Additionally, the Board authorized an unsecured loan of up to ₹50 crore to SMS Peptides Private Limited, in which SMS Pharmaceuticals holds a 99.99% stake. The loan is intended for business purposes and will be executed subsequent to shareholder approval at the ensuing general meeting. The transaction is considered to be at arm’s length, with no outstanding amount as of the disclosure date.

The 38th AGM for FY25-26 is scheduled for September 23, 2026, via Video Conference or Other Audio-Visual Means. The register of members and share transfer books will remain closed from September 17, 2026, to September 23, 2026. The record date for dividend entitlement is fixed for September 16, 2026.

What the Numbers Show

The divergence between revenue growth and profit growth warrants attention. While revenue increased by 5.6% year-on-year, consolidated net profit attributable to shareholders grew by only 2.0%. This suggests that cost pressures or lower margins in certain product lines may have offset the benefits of higher sales volume. Furthermore, the significant decline in the share of profit from associate VKT Pharma Private Limited—from ₹177.58 lakh in Q1FY26 to ₹70.80 lakh in Q1FY27—highlights volatility in joint venture contributions. Investors should monitor whether this trend persists in subsequent quarters, as it could impact overall group profitability despite stable core operations.

SMS Pharmaceuticals reported a broad-based improvement in its financial performance for Q1, with revenue, profitability, and operating margins all registering year-on-year gains. The company's top line grew to 2.07B rupees compared to 1.96B rupees in the corresponding quarter of the previous year, reflecting steady business momentum.

Operating Performance

The company's EBITDA rose to 419M rupees in Q1 from 389M rupees in the year-ago period, signalling improved operational efficiency. The EBITDA margin also expanded on a year-on-year basis, moving from 19.82% to 20.24%, indicating better cost management relative to revenue growth. The following table summarises the key operating metrics:

Bottom-Line Growth

SMS Pharmaceuticals' standalone net profit for Q1 came in at 211M rupees, up from 182M rupees reported in the same quarter of the prior year. The year-on-year increase in net profit underscores the company's ability to translate top-line growth and margin improvements into stronger earnings. The combination of higher revenue and disciplined cost control contributed to the improved profitability outcome for the quarter.